@MM1 – No, I have not. I do think, however, if Tidepool’s initial iOS design of an interoperable automated glycemic controller (iAGC) is approved by the FDA and embraced by commercial concerns, it only makes sense that an Android-based iAGC app would follow to serve this much larger market. That’s a lot of “ifs” and I hope that scenario plays out.
It would require that the current commercial players abandon any hope of their wish to maintain their proprietary commercial silos. The FDA’s enabling of the iAGC along with the pump and CGM standards makes this possible.
Tidepool’s success means the patient’s voice will be heard and acted upon.